ClinicalTrials.gg
CompletedNCT03052322Auriel-RAUpdated Dec 20, 2019Results posted

MSB11022 in Moderate to Severe Rheumatoid Arthritis

A Phase 3 interventional study of MSB11022 and EU-Humira in Moderate to Severe Rheumatoid Arthritis, sponsored by Fresenius Kabi SwissBioSim GmbH. Completed at 46 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-20.

Sponsored by Fresenius Kabi SwissBioSim GmbH (part of Fresenius Kabi) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
288
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.

Enrollment
34th of 87
288 · median 160
Started
2017
the only one that year
Phase 3
36 of 87
1 open now
Registered
75th of 87
by date
Lead sponsor
2 of 87
Fresenius Kabi SwissBioSim GmbH

Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 34th largest by enrollment, is the only one that started in 2017, is one of 36 in phase 3, and was the 75th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing adalimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy, safety and immunogenicity of MSB11022 and Humira® in adult participants with rheumatoid arthritis (RA).

03

Conditions studied

  • Moderate to Severe Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of rheumatoid arthritis based on 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria
  • At least 6 tender (of 68 assessed) and 6 swollen (of 66 assessed) joints at screening and baseline
  • Must have received methotrexate for at least 12 weeks and been on a stable dose for at least 4 weeks prior to the first study dose
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Evidence of untreated or inadequately treated latent or active Tuberculosis
  • Evidence of uncontrolled, diseases
  • Any second disease-modifying antirheumatic drugs must be washed out prior to the first study dose
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
288 participants (actual)

Study arms

  • Experimental
    MSB11022

    Drug: MSB11022

  • Active comparator
    EU-Humira

    Drug: EU-Humira

Interventions

  • Participants received MSB11022 (modified buffer and stabilizer) subcutaneously at dose of 40 milligram (mg) every other week from Day 1 up to Week 48.

    Also known as: Adalimumab

  • DrugEU-Humira

    Participants received EU-Humira subcutaneously at dose of 40 mg every other week from Day 1 up to Week 48.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-emergent Adverse Events of Special Interest (AESI)

    Adverse event (AE) was defined as any untoward medical occurrence in participants, which does not necessarily have causal relationship with treatment. Term Treatment-emergent Adverse Events (TEAE) is defined as AEs starting/worsening after first intake of the study drug. Hypersensitivity was the pre-defined TEAE of special Interest for this study. The percentage of participants with treatment emergent AESIs (hypersensitivity) were reported.

    Time frame: Up to Week 52

Secondary outcomes

  1. Percentage of Participants Who Achieved American College of Rheumatology 20 (ACR20) Response at Week 12

    The ACR 20 Response is defined as greater than or equal to (\>=) 20 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>=20 percent improvement in 3 of following 5 assessments: participant's assessment of pain using Visual Analog Scale (VAS ; 0-10 millimeter \[mm\], 0 mm=no pain and 10 mm=worst possible pain), participant's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas). The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and acute-phase marker (CRP).

    Time frame: Week 12

  2. Percentage of Participants With Positive Anti-Drug Antibodies (ADAs) Status to Adalimumab

    Percentage of participants with positive anti-Drug antibodies (ADAs) status to Adalimumab were reported.

    Time frame: Baseline, Week 2, 4, 12, 24, 36 and 52

  3. Anti-Drug Antibodies (ADAs) Titer Levels for Adalimumab

    Titer was defined as the degree to which the antibody-serum sample could be diluted and still contained detectable amounts of antibody. Anti-Drug Antibodies (ADAs) titers for adalimumab was reported. Data was collected using validated bioanalytical method.

    Time frame: Baseline, Week 2, 4, 12, 24, 36 and 52

  4. Percentage of Participants With Confirmed Neutralizing Antibodies (NAb) Status to Adalimumab

    Percentage of participants with confirmed neutralizing antibodies status to Adalimumab were reported.

    Time frame: Baseline, Week 2, 4, 12, 24, 36 and 52

  5. Percentage of Participants Who Achieved American College of Rheumatology 20 (ACR20) Response at Week 2, 4, 8, 24 and 52

    The ACR 20 Response is defined as greater than or equal to (\>=) 20 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>=20 percent improvement in 3 of following 5 assessments: patient's assessment of pain using Visual Analog Scale (VAS ; 0-10 millimeter \[mm\], 0 mm=no pain and 10 mm=worst possible pain), patient's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas). The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and acute-phase marker (CRP).

    Time frame: Week 2, 4, 8, 24 and 52

  6. Percentage of Participants Who Achieved American College of Rheumatology 50 (ACR50) Response at Week 2, 4, 8, 12, 24 and 52

    The ACR 50 Response is defined as greater than or equal to (\>=) 50 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>=50 percent improvement in 3 of following 5 assessments: patient's assessment of pain using Visual Analog Scale (VAS ; 0-10 millimeter \[mm\], 0 mm=no pain and 10 mm=worst possible pain), patient's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas). The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and acute-phase marker (CRP).

    Time frame: Week 2, 4, 8, 12, 24 and 52

  7. Percentage of Participants Who Achieved American College of Rheumatology 70 (ACR70) Response at Week 2, 4, 8, 12, 24 and 52

    The ACR 70 Response is defined as greater than or equal to (\>=) 70 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>=70 percent improvement in 3 of following 5 assessments: patient's assessment of pain using Visual Analog Scale (VAS ; 0-10 millimeter \[mm\], 0 mm=no pain and 10 mm=worst possible pain), patient's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas). The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and acute-phase marker (CRP).

    Time frame: Week 2, 4, 8, 12, 24 and 52

  8. Change From Baseline in Disease Activity Score Based on a 28 Joint Count- Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 2, 4, 8, 12, 24 and 52

    DAS calculated on 28 joints is composite score derived from 4 measures: number of swollen joints (out of 28), number of tender joints (out of 28), Erythrocyte sedimentation rate (ESR), Patient's Global Assessment of Disease Activity on visual analog scale (VAS). Overall disease activity score DAS28 was derived using following formulas from DAS28:DAS28=0.56\*√(TJC28)+0.28\*√(SJC28) + 0.014\*GH+0.70\*ln(ESR). Where: TJC28 = 28 joint count for tenderness, SJC28 = 28 joint count for swelling, ln(ESR) = natural log of ESR, GH = general health component of DAS (ie, Patient's Global Assessment of Disease Activity, assessed using scale of 1-100 where 100 is maximal activity); For analyses, GH divided by 10 \& converted to 0.5 scale, i.e, 0, 0.5, 1, 1.5. DAS28-ESR of \>5.1 implies active disease, \<3.2 low disease activity, \& \<2.6 remission. Change of 1.2(twice measurement error)=significant change of disease activity state. Overall score ranges from 0-10 where higher score means more severe disease.

    Time frame: Baseline, Week 2, 4, 8, 12, 24 and 52

  9. Percentage of Participants With Disease Activity Score Based on 28-joints Count- Erythrocyte Sedimentation Rate (DAS28-ESR) Low Disease Activity and Remission at Week 2, 4, 8, 12, 24, and 52

    Disease Activity Score calculated on 28 joints is composite score derived from 4 measures: number of swollen joints (out of 28), -number of tender joints (out of 28), -Erythrocyte sedimentation rate (ESR), -Patient's Global Assessment of Disease Activity on visual analog scale (VAS). Overall disease activity score DAS28 was derived using following formulas from DAS28: DAS28=0.56\*√(TJC28)+0.28\*√(SJC28) + 0.014\*GH+0.70\*ln(ESR). Where: -TJC28 = 28 joint count for tenderness, -SJC28 = 28 joint count for swelling, -ln(ESR) = natural logarithm of ESR, -GH = general health component of DAS (ie, Patient's Global Assessment of Disease Activity, assessed using scale of 1 to 100 where 100 is maximal activity); For analyses, GH was divided by 10 and converted to a 0.5 scale, i.e., 0, 0.5, 1, 1.5. DAS28-ESR of \>5.1 implies active disease, \<3.2 low disease activity, and \<2.6 remission.

    Time frame: Week 2, 4, 8, 12, 24, and 52

  10. Change From Baseline in Simplified Disease Activity Index (SDAI) Total Score at Week 2, 4, 8, 12, 24, and 52

    SDAI is numerical sum of 5 outcome parameters: tender \& swollen joint count (based on 28-joint assessment), Patient's \& Physician's Global Assessment of Disease Activity (VAS) \& level of C-reactive protein (CRP)(milligram per deciliter (mg/dL), normal\<1 mg/dL). SDAI was calculated based on following formula: SDAI = 28 joint count for swelling (SJC28) + 28 joint count for tenderness (TJC28)+GH+PGA+CRP Where: -GH =general health component of DAS (i.e. Patient's Global Assessment of Disease Activity, assessed using scale of 1 to 100 where 100 is maximal activity; For analyses, GH was divided by 10 \& converted to 0.5 scale (0, 0.5, 1, 1.5).-PGA = Physician's Global Assessment of Disease Activity assessed using scale of 1 to 100 where 100 is maximal activity. For analyses, PGA will be divided by 10 \& converted to 0.5 scale (0, 0.5, 1, 1.5). where \[0-0.25\] = 0, \[0.25-0.75\] = 0.5, \[0.76-1.25\] = 1, etc. The total score range is 0-86 \& lower score indicates less disease activity.

    Time frame: Baseline, Week 2, 4, 8, 12, 24, and 52

  11. Change From Baseline in Clinical Disease Activity Index (CDAI) Total Score at Week 2, 4, 8, 12, 24 and 52

    Clinical Disease Activity Index (CDAI) is a composite index (without acute-phase reactant) for assessing disease activity. The CDAI was calculated based on following formula: CDAI = 28 joint count for swelling (SJC28) + 28 joint count for tenderness (TJC28) + GH + PGA. Where, -GH = general health component of the DAS (i.e., Patient's Global Assessment of Disease Activity, assessed using a scale of 1 to 100 where 100 is maximal activity; for analyses, GH was divided by 10 and converted to a 0.5 scale, i.e., 0, 0.5, 1, 1.5 etc. where \[0-0.25\] = 0, \[0.25-0.75\] = 0.5, \[0.76-1.25\] = 1, etc.). -PGA = Physician's Global Assessment of Disease Activity assessed using a scale of 1 to 100 where 100 is maximal activity. For analyses, PGA was divided by 10 and converted to a 0.5 scale, ie, 0, 0.5, 1, 1.5 etc. where \[0-0.25\] = 0, \[0.25-0.75\] = 0.5, \[0.76-1.25\] = 1, etc. The CDAI ranges from 0 to 76. Lower score indicates less disease activity.

    Time frame: Baseline, Week 2, 4, 8, 12, 24 and 52

  12. Percentage of Participants With American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission at Week 2, 4, 8, 12, 24 and 52

    According to Boolean-based definition of remission of ACR/EULAR, a participant must satisfy all of the following: tender joint count \<= 1, swollen joint count \<= 1, CRP \<= 1 mg/dL, and Patient's Global Assessment of Disease Activity \<= 1 (0 to 10 VAS). PGA was assessed on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition.

    Time frame: Week 2, 4, 8, 12, 24 and 52

  13. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Death

    Adverse event(AE) was defined as any untoward medical occurrence in participants which does not necessarily have causal relationship with treatment. A serious adverse event(SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Term TEAE is defined as AEs starting/worsening after first intake of the study drug. All abnormal physical examinations occurring during the study have been reported as Adverse events. TEAEs included both Serious TEAEs and non-serious TEAEs.

    Time frame: Baseline up to Week 69

  14. Percentage of Participants With Clinically Meaningful Differences in Vital Signs

    Vital signs including body temperature, respiratory rate, and heart rate (after 5-minute rest) were measured. Percentage of participants with clinically meaningful abnormalities in vital signs were reported. Clinical meaningful was determined by the investigator.

    Time frame: Up to Week 52

  15. Percentage of Participants With Clinically Meaningful Differences in Laboratory Values

    Laboratory parameters including hematology, urinalysis, and biochemistry analysis were analyzed.

    Time frame: Up to Week 52

  16. Percentage of Participants With Clinically Significant Abnormal Values for 12-lead Electrocardiogram (ECG) at Week 12, 24, and 52

    Percentage of participants with clinically significant abnormal values for 12-lead electrocardiogram (ECG) at week 12, 24, and 52 were reported.

    Time frame: Week 12, 24, and 52

  17. Percentage of Participants With Anti-Nuclear Antibody (ANA) and Anti Double-stranded Deoxyribonucleic Acid (Anti-dsDNA) at Baseline, Week 24 and 52

    For ANA, positivity is defined as any participant with ANA titer greater than (\>) 1:160 and negativity is defined as ANA titer less than (\<) 1:160. For anti-ds DNA, positivity is defined as any participant with adsDNA \> 15 units per milliliter (U/mL), intermediate category is defined as value between 10 U/mL to 15 U/mL and negativity is defined as adsDNA \< 10 U/mL. Percentage of participants with anti-nuclear antibody (ANA) and anti double-stranded deoxyribonucleic acid (Anti-dsDNA) at baseline, week 24 and 52 were reported.

    Time frame: Baseline, Week 24 and 52

  18. Health Assessment Questionnaire Disability Index (HAQ-DI) Total Score at Baseline, Weeks 12, 24 and 52

    The HAQ-DI is a participant-reported questionnaire that is commonly used in RA to measure disease associated disability (assessment of physical function). It consists of several questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. HAQ-DI scores range from 0 to 3. The disability section of the questionnaire scores the participant's self-perception on the degree of difficulty (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do).

    Time frame: Baseline, Weeks 12, 24 and 52

  19. Short-Form Health Survey- 36 Items (SF-36) at Baseline, Week 12, 24 and 52

    The Short Form Health Survey (SF-36) is a validated 36-item, patient-reported indication of overall health status not specific to any age, disease or Treatment group. The SF-36 questionnaire contains 36 questions pertaining to eight subscales of health status. These eight subscales were summarized as relating to either physical health or mental health. Physical component summary (PCS) is based primarily on physical functioning, role-physical, bodily pain, and general health scales and mental component summary (MCS) encompasses vitality, social functioning, role-emotional, and mental health scales. Score from mental health, role emotional, social functioning, and vitality domains were averaged to calculate MCS. Total score range for MCS was 0-100 (100=highest level of mental functioning). Score from physical function, role physical, bodily pain, and general health domains were averaged to calculate PCS. Total score range for PCS was 0-100 (100=highest level of physical functioning).

    Time frame: Baseline, Week 12, 24 and 52

  20. Euro-Quality of Life - 5 Dimension-5 Levels (EQ-5D-5L) Utility Index Score at Baseline, Week 12, 24 and 52

    EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The EQ-5D-5L descriptive system provides a profile of the participant's health state 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level in each of the 5 dimensions. Responses to the 5 dimension scores were combined and converted into a single preference-weighted health utility index score 0 (0.0- worst health state) to 1 (1.0- better health state) representing the general health status of the individual based on the UK scoring algorithm.

    Time frame: Baseline, Week 12, 24 and 52

  21. Euro-Quality of Life - 5 Dimension-5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) Score at Baseline, Week 12, 24 and 52

    EQ-5D-5L: Standardized, participant-rated questionnaire to assess health-related quality of life. EQ-5D-5L includes 2 components: EQ-5D-5L health state profile (descriptive system) and EQ-5D-5L Visual Analog Scale. EQ-5D-5L descriptive system provides a profile of participant's health state 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. Responses to 5 dimension scores were combined and converted into single preference-weighted health utility index score 0 (worst health state) to 1 (better health state). EQ-VAS: Self-rated health status using a vertical VAS. EQ-VAS records participant's perceptions of their own current overall health in range from 0 (worst imaginable health) to 100 (best imaginable health).

    Time frame: Baseline, Week 12, 24 and 52

  22. Mean Change From Baseline (Week 4) in Injection Site Pain as Assessed by Visual Analogue Scale (VAS) at Week 6 and 8

    The participant's reported perception of pain was measured on a VAS where the slash drawn by the participant represents pain of increasing intensity. VAS score ranges from 0-10 millimeter \[mm\], where; 0 mm=no pain and 10 mm=worst possible pain. The first 2 injections was administered by qualified personnel. The next three doses of IMP (3-5) will be self-administered by the participant and injection site pain was assessed. Pain was recorded immediately after, 15 minutes after, and 1 hour after the injections received by the participants.

    Time frame: Immediately, 15 minutes and 1 hour post-injection on Baseline (Week 4), Week 6 and 8

07

Results

Posted Apr 23, 2019

Participant flow

Participant flow — Overall Study
MilestoneMSB11022EU-Humira
Started143145
Completed122113
Not completed2132
Withdrew: Other un-specified12
Withdrew: Withdrawal by subject109
Withdrew: Death02
Withdrew: Lack of efficacy12
Withdrew: Protocol violation10
Withdrew: Lost to follow-up24
Withdrew: Adverse event613

Outcome measures

PrimaryPercentage of Participants With Treatment-emergent Adverse Events of Special Interest (AESI)

Adverse event (AE) was defined as any untoward medical occurrence in participants, which does not necessarily have causal relationship with treatment. Term Treatment-emergent Adverse Events (TEAE) is defined as AEs starting/worsening after first intake of the study drug. Hypersensitivity was the pre-defined TEAE of special Interest for this study. The percentage of participants with treatment emergent AESIs (hypersensitivity) were reported.

Time frame:
Up to Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With Treatment-emergent Adverse Events of Special Interest (AESI)
Percentage of ParticipantsMSB11022EU-Humira
Percentage of Participants With Treatment-emergent Adverse Events of Special Interest (AESI)4.2 (1.6 to 8.9)5.5 (2.4 to 10.6)
SecondaryPercentage of Participants Who Achieved American College of Rheumatology 20 (ACR20) Response at Week 12

The ACR 20 Response is defined as greater than or equal to (\>=) 20 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>=20 percent improvement in 3 of following 5 assessments: participant's assessment of pain using Visual Analog Scale (VAS ; 0-10 millimeter \[mm\], 0 mm=no pain and 10 mm=worst possible pain), participant's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas). The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and acute-phase marker (CRP).

Time frame:
Week 12
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved American College of Rheumatology 20 (ACR20) Response at Week 12
Percentage of ParticipantsMSB11022EU-Humira
Percentage of Participants Who Achieved American College of Rheumatology 20 (ACR20) Response at Week 1279.6 (72.0 to 85.9)80.9 (73.4 to 86.9)
SecondaryPercentage of Participants With Positive Anti-Drug Antibodies (ADAs) Status to Adalimumab

Percentage of participants with positive anti-Drug antibodies (ADAs) status to Adalimumab were reported.

Time frame:
Baseline, Week 2, 4, 12, 24, 36 and 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With Positive Anti-Drug Antibodies (ADAs) Status to Adalimumab
Percentage of ParticipantsMSB11022EU-Humira
Baseline7.74.2
Week 220.315.2
Week 429.821.3
Week 1254.248.6
Week 2471.961.7
Week 3666.965.3
Week 5260.862.2
SecondaryAnti-Drug Antibodies (ADAs) Titer Levels for Adalimumab

Titer was defined as the degree to which the antibody-serum sample could be diluted and still contained detectable amounts of antibody. Anti-Drug Antibodies (ADAs) titers for adalimumab was reported. Data was collected using validated bioanalytical method.

Time frame:
Baseline, Week 2, 4, 12, 24, 36 and 52
Reported as:
Median · Titer
Anti-Drug Antibodies (ADAs) Titer Levels for Adalimumab
TiterMSB11022EU-Humira
Baseline4.0 (1 to 512)1.5 (1 to 8)
Week 24.0 (1 to 32768)12.0 (1 to 1024)
Week 46.0 (1 to 16384)6.0 (1 to 512)
Week 1216.0 (1 to 4096)16.0 (1 to 16384)
Week 2416.0 (1 to 32768)24.0 (1 to 131072)
Week 3616.0 (1 to 32768)16.0 (1 to 131072)
Week 5216.0 (1 to 16384)12.0 (1 to 32768)
SecondaryPercentage of Participants With Confirmed Neutralizing Antibodies (NAb) Status to Adalimumab

Percentage of participants with confirmed neutralizing antibodies status to Adalimumab were reported.

Time frame:
Baseline, Week 2, 4, 12, 24, 36 and 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With Confirmed Neutralizing Antibodies (NAb) Status to Adalimumab
Percentage of ParticipantsMSB11022EU-Humira
Baseline45.550.0
Week 231.040.9
Week 433.330.0
Week 1233.838.2
Week 2427.029.3
Week 3624.129.1
Week 5232.939.2
SecondaryPercentage of Participants Who Achieved American College of Rheumatology 20 (ACR20) Response at Week 2, 4, 8, 24 and 52

The ACR 20 Response is defined as greater than or equal to (\>=) 20 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>=20 percent improvement in 3 of following 5 assessments: patient's assessment of pain using Visual Analog Scale (VAS ; 0-10 millimeter \[mm\], 0 mm=no pain and 10 mm=worst possible pain), patient's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas). The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and acute-phase marker (CRP).

Time frame:
Week 2, 4, 8, 24 and 52
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved American College of Rheumatology 20 (ACR20) Response at Week 2, 4, 8, 24 and 52
Percentage of ParticipantsMSB11022EU-Humira
Week 230.0 (22.55 to 38.32)29.7 (22.36 to 37.80)
Week 452.1 (43.58 to 60.56)52.8 (44.29 to 61.15)
Week 871.1 (62.93 to 78.42)72.9 (64.89 to 79.98)
Week 2488.5 (81.98 to 93.28)83.3 (75.86 to 89.25)
Week 5281.8 (73.78 to 88.24)86.4 (78.92 to 92.05)
SecondaryPercentage of Participants Who Achieved American College of Rheumatology 50 (ACR50) Response at Week 2, 4, 8, 12, 24 and 52

The ACR 50 Response is defined as greater than or equal to (\>=) 50 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>=50 percent improvement in 3 of following 5 assessments: patient's assessment of pain using Visual Analog Scale (VAS ; 0-10 millimeter \[mm\], 0 mm=no pain and 10 mm=worst possible pain), patient's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas). The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and acute-phase marker (CRP).

Time frame:
Week 2, 4, 8, 12, 24 and 52
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved American College of Rheumatology 50 (ACR50) Response at Week 2, 4, 8, 12, 24 and 52
Percentage of ParticipantsMSB11022EU-Humira
Week 26.4 (2.9 to 11.9)6.2 (2.9 to 11.5)
Week 417.6 (11.7 to 24.9)19.4 (13.3 to 26.9)
Week 840.8 (32.7 to 49.4)34.7 (26.9 to 43.1)
Week 1254.2 (45.7 to 62.6)51.1 (42.5 to 59.6)
Week 2465.5 (56.9 to 73.3)60.6 (51.7 to 68.9)
Week 5264.5 (55.3 to 72.9)66.1 (56.8 to 74.6)
SecondaryPercentage of Participants Who Achieved American College of Rheumatology 70 (ACR70) Response at Week 2, 4, 8, 12, 24 and 52

The ACR 70 Response is defined as greater than or equal to (\>=) 70 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>=70 percent improvement in 3 of following 5 assessments: patient's assessment of pain using Visual Analog Scale (VAS ; 0-10 millimeter \[mm\], 0 mm=no pain and 10 mm=worst possible pain), patient's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas). The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and acute-phase marker (CRP).

Time frame:
Week 2, 4, 8, 12, 24 and 52
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved American College of Rheumatology 70 (ACR70) Response at Week 2, 4, 8, 12, 24 and 52
Percentage of ParticipantsMSB11022EU-Humira
Week 20.7 (0.0 to 3.9)0.7 (0.0 to 3.8)
Week 44.9 (2.0 to 9.9)2.8 (0.8 to 6.9)
Week 814.8 (9.4 to 21.7)12.5 (7.6 to 19.0)
Week 1226.8 (19.7 to 34.8)19.9 (13.6 to 27.4)
Week 2433.8 (26.0 to 42.3)35.6 (27.5 to 44.4)
Week 5239.7 (30.9 to 48.9)42.4 (33.3 to 51.8)
SecondaryChange From Baseline in Disease Activity Score Based on a 28 Joint Count- Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 2, 4, 8, 12, 24 and 52

DAS calculated on 28 joints is composite score derived from 4 measures: number of swollen joints (out of 28), number of tender joints (out of 28), Erythrocyte sedimentation rate (ESR), Patient's Global Assessment of Disease Activity on visual analog scale (VAS). Overall disease activity score DAS28 was derived using following formulas from DAS28:DAS28=0.56\*√(TJC28)+0.28\*√(SJC28) + 0.014\*GH+0.70\*ln(ESR). Where: TJC28 = 28 joint count for tenderness, SJC28 = 28 joint count for swelling, ln(ESR) = natural log of ESR, GH = general health component of DAS (ie, Patient's Global Assessment of Disease Activity, assessed using scale of 1-100 where 100 is maximal activity); For analyses, GH divided by 10 \& converted to 0.5 scale, i.e, 0, 0.5, 1, 1.5. DAS28-ESR of \>5.1 implies active disease, \<3.2 low disease activity, \& \<2.6 remission. Change of 1.2(twice measurement error)=significant change of disease activity state. Overall score ranges from 0-10 where higher score means more severe disease.

Time frame:
Baseline, Week 2, 4, 8, 12, 24 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in Disease Activity Score Based on a 28 Joint Count- Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 2, 4, 8, 12, 24 and 52
Units on a scaleMSB11022EU-Humira
Change at Week 2-0.9 ± 0.9-0.7 ± 0.9
Change at Week 4-1.4 ± 1.1-1.2 ± 1.0
Change at Week 8-1.9 ± 0.9-1.7 ± 1.1
Change at Week 12-2.4 ± 1.1-2.1 ± 1.2
Change at Week 24-2.7 ± 1.0-2.3 ± 1.2
Change at Week 52-2.8 ± 1.1-2.5 ± 1.1
SecondaryPercentage of Participants With Disease Activity Score Based on 28-joints Count- Erythrocyte Sedimentation Rate (DAS28-ESR) Low Disease Activity and Remission at Week 2, 4, 8, 12, 24, and 52

Disease Activity Score calculated on 28 joints is composite score derived from 4 measures: number of swollen joints (out of 28), -number of tender joints (out of 28), -Erythrocyte sedimentation rate (ESR), -Patient's Global Assessment of Disease Activity on visual analog scale (VAS). Overall disease activity score DAS28 was derived using following formulas from DAS28: DAS28=0.56\*√(TJC28)+0.28\*√(SJC28) + 0.014\*GH+0.70\*ln(ESR). Where: -TJC28 = 28 joint count for tenderness, -SJC28 = 28 joint count for swelling, -ln(ESR) = natural logarithm of ESR, -GH = general health component of DAS (ie, Patient's Global Assessment of Disease Activity, assessed using scale of 1 to 100 where 100 is maximal activity); For analyses, GH was divided by 10 and converted to a 0.5 scale, i.e., 0, 0.5, 1, 1.5. DAS28-ESR of \>5.1 implies active disease, \<3.2 low disease activity, and \<2.6 remission.

Time frame:
Week 2, 4, 8, 12, 24, and 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With Disease Activity Score Based on 28-joints Count- Erythrocyte Sedimentation Rate (DAS28-ESR) Low Disease Activity and Remission at Week 2, 4, 8, 12, 24, and 52
Percentage of ParticipantsMSB11022EU-Humira
Low Disease Activity: Week 210.0 (5.6 to 16.2)8.3 (4.4 to 14.0)
Low Disease Activity: Week 420.6 (14.2 to 28.2)16.0 (10.4 to 23.0)
Low Disease Activity: Week 833.1 (25.4 to 41.5)33.3 (25.7 to 41.7)
Low Disease Activity: Week 1246.5 (38.1 to 55.0)42.6 (34.3 to 51.2)
Low Disease Activity: Week 2455.1 (46.4 to 63.5)53.8 (44.9 to 62.5)
Low Disease Activity: Week 5257.0 (47.7 to 65.9)56.8 (47.3 to 65.9)
Remission: Week 23.6 (1.2 to 8.1)2.1 (0.4 to 5.9)
Remission: Week 47.8 (3.9 to 13.5)6.9 (3.4 to 12.4)
Remission: Week 818.3 (12.3 to 25.7)16.0 (10.4 to 23.0)
Remission: Week 1229.6 (22.2 to 37.8)24.1 (17.3 to 32.0)
Remission: Week 2431.2 (23.6 to 39.6)34.1 (26.0 to 42.8)
Remission: Week 5240.5 (31.7 to 49.8)36.4 (27.8 to 45.8)
SecondaryChange From Baseline in Simplified Disease Activity Index (SDAI) Total Score at Week 2, 4, 8, 12, 24, and 52

SDAI is numerical sum of 5 outcome parameters: tender \& swollen joint count (based on 28-joint assessment), Patient's \& Physician's Global Assessment of Disease Activity (VAS) \& level of C-reactive protein (CRP)(milligram per deciliter (mg/dL), normal\<1 mg/dL). SDAI was calculated based on following formula: SDAI = 28 joint count for swelling (SJC28) + 28 joint count for tenderness (TJC28)+GH+PGA+CRP Where: -GH =general health component of DAS (i.e. Patient's Global Assessment of Disease Activity, assessed using scale of 1 to 100 where 100 is maximal activity; For analyses, GH was divided by 10 \& converted to 0.5 scale (0, 0.5, 1, 1.5).-PGA = Physician's Global Assessment of Disease Activity assessed using scale of 1 to 100 where 100 is maximal activity. For analyses, PGA will be divided by 10 \& converted to 0.5 scale (0, 0.5, 1, 1.5). where \[0-0.25\] = 0, \[0.25-0.75\] = 0.5, \[0.76-1.25\] = 1, etc. The total score range is 0-86 \& lower score indicates less disease activity.

Time frame:
Baseline, Week 2, 4, 8, 12, 24, and 52
Reported as:
Mean · Units on a scale
Change From Baseline in Simplified Disease Activity Index (SDAI) Total Score at Week 2, 4, 8, 12, 24, and 52
Units on a scaleMSB11022EU-Humira
Change at Week 2-11.5 ± 10.6-9.1 ± 10.0
Change at Week 4-18.0 ± 11.3-16.0 ± 10.9
Change at Week 8-24.0 ± 10.6-21.4 ± 11.0
Change at Week 12-27.9 ± 10.8-24.7 ± 10.9
Change at Week 24-31.4 ± 11.2-27.8 ± 10.6
Change at Week 52-31.5 ± 11.6-29.1 ± 10.8
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI) Total Score at Week 2, 4, 8, 12, 24 and 52

Clinical Disease Activity Index (CDAI) is a composite index (without acute-phase reactant) for assessing disease activity. The CDAI was calculated based on following formula: CDAI = 28 joint count for swelling (SJC28) + 28 joint count for tenderness (TJC28) + GH + PGA. Where, -GH = general health component of the DAS (i.e., Patient's Global Assessment of Disease Activity, assessed using a scale of 1 to 100 where 100 is maximal activity; for analyses, GH was divided by 10 and converted to a 0.5 scale, i.e., 0, 0.5, 1, 1.5 etc. where \[0-0.25\] = 0, \[0.25-0.75\] = 0.5, \[0.76-1.25\] = 1, etc.). -PGA = Physician's Global Assessment of Disease Activity assessed using a scale of 1 to 100 where 100 is maximal activity. For analyses, PGA was divided by 10 and converted to a 0.5 scale, ie, 0, 0.5, 1, 1.5 etc. where \[0-0.25\] = 0, \[0.25-0.75\] = 0.5, \[0.76-1.25\] = 1, etc. The CDAI ranges from 0 to 76. Lower score indicates less disease activity.

Time frame:
Baseline, Week 2, 4, 8, 12, 24 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI) Total Score at Week 2, 4, 8, 12, 24 and 52
Units on a scaleMSB11022EU-Humira
Change at Week 2-10.8 ± 10.3-8.5 ± 9.9
Change at Week 4-17.4 ± 11.2-15.2 ± 10.7
Change at Week 8-23.5 ± 10.6-20.6 ± 10.9
Change at Week 12-27.4 ± 10.5-24.1 ± 10.7
Change at Week 24-30.8 ± 10.9-27.1 ± 10.7
Change at Week 52-31.1 ± 11.2-28.5 ± 10.6
SecondaryPercentage of Participants With American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission at Week 2, 4, 8, 12, 24 and 52

According to Boolean-based definition of remission of ACR/EULAR, a participant must satisfy all of the following: tender joint count \<= 1, swollen joint count \<= 1, CRP \<= 1 mg/dL, and Patient's Global Assessment of Disease Activity \<= 1 (0 to 10 VAS). PGA was assessed on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition.

Time frame:
Week 2, 4, 8, 12, 24 and 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission at Week 2, 4, 8, 12, 24 and 52
Percentage of ParticipantsMSB11022EU-Humira
Week 20.7 (0.0 to 3.9)0.0 (0.0 to 2.5)
Week 40.7 (0.0 to 3.9)1.4 (0.2 to 5.1)
Week 83.5 (1.2 to 8.0)4.2 (1.5 to 8.9)
Week 125.7 (2.5 to 10.9)12.1 (7.2 to 18.6)
Week 2411.7 (6.8 to 18.3)8.4 (4.3 to 14.5)
Week 5221.0 (14.1 to 29.4)13.6 (7.9 to 21.1)
SecondaryPercentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Death

Adverse event(AE) was defined as any untoward medical occurrence in participants which does not necessarily have causal relationship with treatment. A serious adverse event(SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Term TEAE is defined as AEs starting/worsening after first intake of the study drug. All abnormal physical examinations occurring during the study have been reported as Adverse events. TEAEs included both Serious TEAEs and non-serious TEAEs.

Time frame:
Baseline up to Week 69
Reported as:
Number · Percentage of Participants
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Death
Percentage of ParticipantsMSB11022EU-Humira
TEAEs58.064.1
Serious TEAEs4.99.7
TEAEs Leading to Death00.7
SecondaryPercentage of Participants With Clinically Meaningful Differences in Vital Signs

Vital signs including body temperature, respiratory rate, and heart rate (after 5-minute rest) were measured. Percentage of participants with clinically meaningful abnormalities in vital signs were reported. Clinical meaningful was determined by the investigator.

Time frame:
Up to Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With Clinically Meaningful Differences in Vital Signs
Percentage of ParticipantsMSB11022EU-Humira
Percentage of Participants With Clinically Meaningful Differences in Vital Signs00
SecondaryPercentage of Participants With Clinically Meaningful Differences in Laboratory Values

Laboratory parameters including hematology, urinalysis, and biochemistry analysis were analyzed.

Time frame:
Up to Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With Clinically Meaningful Differences in Laboratory Values
Percentage of ParticipantsMSB11022EU-Humira
Percentage of Participants With Clinically Meaningful Differences in Laboratory Values00
SecondaryPercentage of Participants With Clinically Significant Abnormal Values for 12-lead Electrocardiogram (ECG) at Week 12, 24, and 52

Percentage of participants with clinically significant abnormal values for 12-lead electrocardiogram (ECG) at week 12, 24, and 52 were reported.

Time frame:
Week 12, 24, and 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With Clinically Significant Abnormal Values for 12-lead Electrocardiogram (ECG) at Week 12, 24, and 52
Percentage of ParticipantsMSB11022EU-Humira
Week 1200
Week 2401.5
Week 5200.8
SecondaryPercentage of Participants With Anti-Nuclear Antibody (ANA) and Anti Double-stranded Deoxyribonucleic Acid (Anti-dsDNA) at Baseline, Week 24 and 52

For ANA, positivity is defined as any participant with ANA titer greater than (\>) 1:160 and negativity is defined as ANA titer less than (\<) 1:160. For anti-ds DNA, positivity is defined as any participant with adsDNA \> 15 units per milliliter (U/mL), intermediate category is defined as value between 10 U/mL to 15 U/mL and negativity is defined as adsDNA \< 10 U/mL. Percentage of participants with anti-nuclear antibody (ANA) and anti double-stranded deoxyribonucleic acid (Anti-dsDNA) at baseline, week 24 and 52 were reported.

Time frame:
Baseline, Week 24 and 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With Anti-Nuclear Antibody (ANA) and Anti Double-stranded Deoxyribonucleic Acid (Anti-dsDNA) at Baseline, Week 24 and 52
Percentage of ParticipantsMSB11022EU-Humira
Baseline: ANA: Negative97.295.1
Baseline: ANA: Positive2.84.9
Week 24: ANA: Negative92.091.6
Week 24: ANA: Positive8.08.4
Week 52: ANA: Negative78.884.7
Week 52: ANA: Positive21.215.3
Baseline: Anti-dsDNA: Negative97.998.6
Baseline: Anti-dsDNA: Intermediate1.40.7
Baseline: Anti-dsDNA: Positive0.70.7
Week 24: Anti-dsDNA: Negative95.796.2
Week 24: Anti-dsDNA: Intermediate2.23.0
Week 24: Anti-dsDNA: Positive2.20.8
Week 52: Anti-dsDNA: Negative95.097.5
Week 52: Anti-dsDNA: Intermediate0.81.7
Week 52: Anti-dsDNA: Positive4.10.8
SecondaryHealth Assessment Questionnaire Disability Index (HAQ-DI) Total Score at Baseline, Weeks 12, 24 and 52

The HAQ-DI is a participant-reported questionnaire that is commonly used in RA to measure disease associated disability (assessment of physical function). It consists of several questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. HAQ-DI scores range from 0 to 3. The disability section of the questionnaire scores the participant's self-perception on the degree of difficulty (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do).

Time frame:
Baseline, Weeks 12, 24 and 52
Reported as:
Mean · Units on a scale
Health Assessment Questionnaire Disability Index (HAQ-DI) Total Score at Baseline, Weeks 12, 24 and 52
Units on a scaleMSB11022EU-Humira
Baseline1.6 ± 0.61.6 ± 0.6
Week 121.1 ± 0.61.1 ± 0.6
Week 241.0 ± 0.61.0 ± 0.6
Week 520.9 ± 0.70.9 ± 0.6
SecondaryShort-Form Health Survey- 36 Items (SF-36) at Baseline, Week 12, 24 and 52

The Short Form Health Survey (SF-36) is a validated 36-item, patient-reported indication of overall health status not specific to any age, disease or Treatment group. The SF-36 questionnaire contains 36 questions pertaining to eight subscales of health status. These eight subscales were summarized as relating to either physical health or mental health. Physical component summary (PCS) is based primarily on physical functioning, role-physical, bodily pain, and general health scales and mental component summary (MCS) encompasses vitality, social functioning, role-emotional, and mental health scales. Score from mental health, role emotional, social functioning, and vitality domains were averaged to calculate MCS. Total score range for MCS was 0-100 (100=highest level of mental functioning). Score from physical function, role physical, bodily pain, and general health domains were averaged to calculate PCS. Total score range for PCS was 0-100 (100=highest level of physical functioning).

Time frame:
Baseline, Week 12, 24 and 52
Reported as:
Mean · Units on a scale
Short-Form Health Survey- 36 Items (SF-36) at Baseline, Week 12, 24 and 52
Units on a scaleMSB11022EU-Humira
PCS: Baseline30.3 ± 7.630.6 ± 7.8
PCS: Week 1239.0 ± 7.938.6 ± 8.6
PCS: Week 2440.5 ± 8.840.8 ± 9.1
PCS: Week 5241.8 ± 9.541.6 ± 9.3
MCS: Baseline40.9 ± 13.243.4 ± 11.7
MCS: Week 1247.4 ± 11.348.2 ± 11.3
MCS: Week 2449.8 ± 10.848.8 ± 10.9
MCS: Week 5248.0 ± 10.449.3 ± 11.5
SecondaryEuro-Quality of Life - 5 Dimension-5 Levels (EQ-5D-5L) Utility Index Score at Baseline, Week 12, 24 and 52

EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The EQ-5D-5L descriptive system provides a profile of the participant's health state 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level in each of the 5 dimensions. Responses to the 5 dimension scores were combined and converted into a single preference-weighted health utility index score 0 (0.0- worst health state) to 1 (1.0- better health state) representing the general health status of the individual based on the UK scoring algorithm.

Time frame:
Baseline, Week 12, 24 and 52
Reported as:
Mean · Units on a scale
Euro-Quality of Life - 5 Dimension-5 Levels (EQ-5D-5L) Utility Index Score at Baseline, Week 12, 24 and 52
Units on a scaleMSB11022EU-Humira
Baseline0.6 ± 0.20.6 ± 0.2
Week 120.8 ± 0.10.8 ± 0.1
Week 240.8 ± 0.10.8 ± 0.1
Week 520.8 ± 0.20.8 ± 0.1
SecondaryEuro-Quality of Life - 5 Dimension-5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) Score at Baseline, Week 12, 24 and 52

EQ-5D-5L: Standardized, participant-rated questionnaire to assess health-related quality of life. EQ-5D-5L includes 2 components: EQ-5D-5L health state profile (descriptive system) and EQ-5D-5L Visual Analog Scale. EQ-5D-5L descriptive system provides a profile of participant's health state 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. Responses to 5 dimension scores were combined and converted into single preference-weighted health utility index score 0 (worst health state) to 1 (better health state). EQ-VAS: Self-rated health status using a vertical VAS. EQ-VAS records participant's perceptions of their own current overall health in range from 0 (worst imaginable health) to 100 (best imaginable health).

Time frame:
Baseline, Week 12, 24 and 52
Reported as:
Mean · Units on a scale
Euro-Quality of Life - 5 Dimension-5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) Score at Baseline, Week 12, 24 and 52
Units on a scaleMSB11022EU-Humira
Baseline42.4 ± 18.545.4 ± 20.4
Week 1264.6 ± 19.663.2 ± 20.9
Week 2466.2 ± 22.265.6 ± 24.3
Week 5268.8 ± 21.769.0 ± 22.7
SecondaryMean Change From Baseline (Week 4) in Injection Site Pain as Assessed by Visual Analogue Scale (VAS) at Week 6 and 8

The participant's reported perception of pain was measured on a VAS where the slash drawn by the participant represents pain of increasing intensity. VAS score ranges from 0-10 millimeter \[mm\], where; 0 mm=no pain and 10 mm=worst possible pain. The first 2 injections was administered by qualified personnel. The next three doses of IMP (3-5) will be self-administered by the participant and injection site pain was assessed. Pain was recorded immediately after, 15 minutes after, and 1 hour after the injections received by the participants.

Time frame:
Immediately, 15 minutes and 1 hour post-injection on Baseline (Week 4), Week 6 and 8
Reported as:
Mean · Millimeter (mm)
Mean Change From Baseline (Week 4) in Injection Site Pain as Assessed by Visual Analogue Scale (VAS) at Week 6 and 8
Millimeter (mm)MSB11022EU-Humira
Change at Week 6: Immediately post-injection-1.4 ± 5.12-1.3 ± 10.16
Change at Week 6: 15 min post-injection-0.2 ± 2.670.4 ± 3.29
Change at Week 6: 1 hour post-injection0.0 ± 0.660.0 ± 2.67
Change at Week 8: Immediately post-injection-1.7 ± 6.48-2.3 ± 10.35
Change at Week 8: 15 min post-injection-0.3 ± 2.25-0.7 ± 4.12
Change at Week 8: 1 hour post-injection-0.1 ± 0.57-0.7 ± 5.43

Adverse events

Collected over Up to Week 69. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MSB110220/143 (0%)8/143 (5.6%)15/143 (10.5%)
EU-Humira2/145 (1.4%)15/145 (10.3%)34/145 (23.4%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventMSB11022EU-Humira
OsteoarthritisMusculoskeletal and connective tissue disorders1/1432/145
Rheumatoid arthritisMusculoskeletal and connective tissue disorders1/1432/145
Anaphylactic reactionImmune system disorders1/1430/145
Mycobacterium tuberculosis complex test positiveInvestigations1/1431/145
Cervical spinal stenosisMusculoskeletal and connective tissue disorders1/1430/145
Synovial cystMusculoskeletal and connective tissue disorders1/1430/145
Transient global amnesiaNervous system disorders1/1430/145
Device dislocationProduct Issues1/1430/145
Arthritis bacterialInfections and infestations1/1430/145
Arteriosclerosis coronary arteryCardiac disorders0/1431/145
Most frequent other events
Most frequent other events
EventMSB11022EU-Humira
NasopharyngitisInfections and infestations6/14313/145
Injection site erythemaGeneral disorders4/14312/145
Injection site painGeneral disorders2/14310/145
Injection site pruritusGeneral disorders1/1438/145
ErythemaSkin and subcutaneous tissue disorders2/1438/145

Baseline characteristics

Age, Continuous
Age, Continuous(Years)MSB11022EU-HumiraTotal
Mean53.9 ± 11.954.0 ± 11.053.9 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)MSB11022EU-HumiraTotal
Female108119227
Male352661
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MSB11022EU-HumiraTotal
Hispanic or Latino314
Not Hispanic or Latino140144284
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MSB11022EU-HumiraTotal
American Indian or Alaska Native000
Asian022
Native Hawaiian or Other Pacific Islander000
Black or African American000
White142143285
More than one race000
Unknown or Not Reported101
08

Study locations

46 sites
  • MHAT "Trimontium", OOD
    Plovdiv, 4000, Bulgaria
  • MHAT-Plovdiv AD
    Plovdiv, 4002, Bulgaria
  • UMHAT "Kaspela", EOOD
    Plovdiv, 4002, Bulgaria
  • Medical Center "Teodora", EOOD
    Ruse, 7000, Bulgaria
  • MHAT - Ruse, AD
    Ruse, 7002, Bulgaria
  • MHAT - Shumen, AD
    Shumen, 9700, Bulgaria
  • MHAT "Lyulin", EAD
    Sofia, 1336, Bulgaria
  • Medical Center "Excelsior", OOD
    Sofia, 1407, Bulgaria
  • UMHAT "Sv. Ivan Rilski", EAD
    Sofia, 1431, Bulgaria
  • DCC 17 - Sofia EOOD
    Sofia, 1504, Bulgaria
  • Military Medical Academy - MHAT - Sofia
    Sofia, 1606, Bulgaria
  • MC "Synexus - Sofia", EOOD
    Sofia, 1784, Bulgaria
  • Revmatologie Bruntal, s.r.o.
    Bruntal, 792 01, Czechia
  • Ccbr-Synarc A/S
    Ostrava, 702 00, Czechia
  • A-SHINE s.r.o.
    Plzen, 31200, Czechia
  • CLINTRIAL s.r.o.
    Praha 10, 100 00, Czechia
  • Revma Praha, s.r.o.
    Praha 13, 158 00, Czechia
  • Revmatologicky Ustav
    Praha 2, 128 50, Czechia
  • Revmatologicka ambulance
    Praha 4 Nusle, 140 00, Czechia
  • Nuselska poliklinika
    Praha 4, 140 00, Czechia
  • MEDICAL PLUS s.r.o.
    Uherske Hradiste, 686 01, Czechia
  • PV - Medical, s.r.o.
    Zlin, 760 01, Czechia
  • Studienambulanz Dr. Wassenberg
    Ratingen, Nordrhein Westfalen 40882, Germany
  • HRF Hamburger Rheuma Forschungszentrum
    Hamburg, 20095, Germany
  • Dr. Kenessey Albert Korhaz-Rendelointezet
    Balassagyarmat, 2660, Hungary
  • Revita Reumatologiai Rendelo
    Budapest, 1023, Hungary
  • Obudai Egeszsegugyi Centrum Kft.
    Budapest, 1036, Hungary
  • DRC Szekesfehervar
    Szekesfehervar, 8000, Hungary
  • Mentahaz Maganorvosi Kozpont
    Szekesfehervar, 8000, Hungary
  • Vital Medical Center
    Veszprem, 8200, Hungary
  • Synexus Magyarorszag Egeszsegugyi Szolgaltato Kft.- Zalaegerszeg AS
    Zalaegerszeg, 8900, Hungary
  • KLIMED Marek Klimkiewicz
    Bialystok, 15-765, Poland
  • ClinicMed Badurski i wspolnicy Spolka Jawna
    Bialystok, 15-879, Poland
  • Szpital Uniwersytecki nr 2 im.dr J. Biziela
    Bydgoszcz, 85-168, Poland
  • Centrum Medyczne Angelius Provita
    Katowice, 40-611, Poland
  • Malopolskie Centrum Medyczne s.c.
    Krakow, 30-510, Poland
  • Centrum Terapii Wspolczesnej J.M. Jasnorzewska sp. komandytowo-akcyjna
    Lodz, 90-242, Poland
  • KLIMED Marek Klimkiewicz
    Lomza, 18-404, Poland
  • RCMed
    Nowy Duninow, 09-505, Poland
  • ETYKA Osrodek Badan Klinicznych
    Olsztyn, 10-117, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej "Nasz Lekarz" Praktyka Grupowa Lekarzy Rodzinnych z
    Torun, 87-100, Poland
  • Medycyna Kliniczna
    Warszawa, 00-660, Poland
  • Rheuma Medicus Zaklad Opieki Zdrowotnej
    Warszawa, 02-118, Poland
  • Niepubliczny Zakład Opieki Zdrowotnej "Biogenes" Sp. z o.o.
    Wroclaw, 53-224, Poland
  • Glasgow Royal Infirmary
    Glasgow, Strathclyde G4 0SF, United Kingdom
  • Whipps Cross University Hospital
    London, E11 1NR, United Kingdom
09

References and documents

Publications

  • Huizinga TWJ, Torii Y, Muniz R. Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity. Rheumatol Ther. 2021 Mar;8(1):41-61. doi: 10.1007/s40744-020-00259-8. Epub 2020 Dec 1. PubMed 33263165 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in May 2018, 15 months.

Results were first posted in Apr 2019, 10 months after primary completion.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 15 months is below that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2017
First posted
Feb 14, 2017
StartActual
Jan 31, 2017
Primary completionActual
May 28, 2018
CompletionActual
Aug 27, 2018
Results first posted
Apr 23, 2019
Last update
Dec 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03052322
Responsible party
Sponsor
First posted
Feb 14, 2017
Start date
Jan 31, 2017
Primary completion
May 28, 2018
Completion
Aug 27, 2018
Results posted
Apr 23, 2019
Last update
Dec 20, 2019

Study contacts

Medical Responsible
study director · Fresenius Kabi SwissBioSim GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion